What is the Flovent patent, and what exactly is being protected?
Flovent is the brand name for inhaled fluticasone propionate, an inhaled corticosteroid used for asthma control. Patents can cover different pieces over time: the active ingredient, specific formulations/devices (especially metered-dose inhalers), manufacturing processes, and other method-of-use claims. The “Flovent patent” people search for usually refers to the patents that block generic or biosimilar competition for fluticasone inhalers in the relevant jurisdiction and time window.
When do Flovent patents expire, and when can generics launch?
Patent “expiration” depends on which specific patent family and jurisdiction you mean (U.S. vs. other countries) and whether there are exclusivity extensions (for example, regulatory exclusivity or market exclusivity terms) that can delay generic entry even after a patent term ends. Generic timelines often hinge on the U.S. Orange Book listing for the exact Flovent product (strength and dosage form), the expiration dates for each listed patent, and any relevant regulatory protections.
If you tell me which Flovent product you mean (for example, Flovent HFA vs. Flovent Diskus), the strength, and the country (U.S.?), I can narrow down the exact patents and dates you’re asking about.
Which Flovent product matters: HFA vs. Diskus?
Yes. Flovent has multiple formulations and delivery devices (notably an HFA metered-dose inhaler and a Diskus dry-powder inhaler). Different patents may apply to different products because they can involve different formulations, device components, and manufacturing methods. So “Flovent patent expiration” results can differ depending on whether you mean HFA or Diskus.
Are there challenges or litigation around Flovent patents?
In the U.S., patent disputes around branded inhalers frequently show up when generic applicants file an Abbreviated New Drug Application (ANDA) with certifications tied to listed patents. Those disputes typically determine when a generic can be launched, not just when patents theoretically end.
What happens if a specific Flovent patent expires but others still exist?
Generic launch can still be blocked by other unexpired patents in the same product’s patent list. Even if one patent expires, a remaining patent (for example, on a device/formulation aspect) can delay entry until it also expires or is ruled invalid/not infringed in litigation.
How to look up the exact Flovent patents (and not guess)
To answer “Flovent patent” accurately, the key is to match the correct product to the regulatory patent listings. The typical workflow is:
- Identify the exact Flovent product (U.S. label variant, strength, and dosage form).
- Check the U.S. FDA Orange Book for that product’s listed patents and expiration dates.
- Separate patent term expiration from any regulatory exclusivity that affects launch timing.
What you can share to get the precise answer
Reply with any of the following and I’ll target the exact patents and timeline:
- Country/jurisdiction (U.S.?)
- Which product: Flovent HFA or Flovent Diskus
- Strength (e.g., 44 mcg, 110 mcg, 220 mcg)
- Whether you’re asking about “first generic entry,” “all generics,” or a specific company’s product
Sources
I don’t have any provided sources for Flovent patent details in your prompt, so I can’t cite specific patent numbers or expiration dates yet. If you want, paste a link or the patent/Orange Book entries you’re looking at, and I’ll interpret them precisely.